Merus N.V. (MRUS) director options cancelled in Genmab $97 cash tender
Rhea-AI Filing Summary
Merus N.V. reported that a director’s share options were cancelled in connection with a cash tender offer by Genmab A/S for all Merus common shares. The offer, made through a Genmab subsidiary, accepted all shares validly tendered as of December 12, 2025 in exchange for $97.00 per share in cash, before taxes, payable as soon as practicable after that time. The reported options covered 13,193 and 17,688 common shares with exercise prices of $41.6 and $48.73; each option was cancelled for cash equal to the offer price minus the exercise price, multiplied by the number of underlying shares.
Positive
- None.
Negative
- None.
Insights
Genmab’s cash tender for Merus triggers cash-out of director options.
Genmab A/S, through its subsidiary, launched a tender offer for all issued and outstanding common shares of Merus N.V.. As of December 12, 2025, the buyer accepted all Merus shares that were validly tendered and not withdrawn, paying $97.00 per share in cash, before interest and taxes, with payment to follow as soon as practicable.
The Form 4 shows a Merus director holding options over 13,193 and 17,688 shares with exercise prices of $41.6 and $48.73 respectively. Under the transaction agreement, these options were cancelled in exchange for cash equal to the Offer Consideration minus the exercise price, multiplied by the number of underlying shares, effectively converting the equity-based awards into cash tied to the $97.00 offer price.
This mechanism aligns option holder treatment with ordinary shareholders in the tender offer, but replaces future equity participation with immediate cash value based on the agreed consideration. The acceptance of tendered shares at a fixed cash price marks a major transition for Merus as an independent public company, with remaining steps governed by the transaction agreement’s terms.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Share Option (right to buy) | 13,193 | $0.00 | -- |
| Disposition | Share Option (right to buy) | 17,688 | $0.00 | -- |
Footnotes (1)
- On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
FAQ
What major corporate event involving Merus N.V. (MRUS) is described?
The content describes a transaction agreement under which a wholly owned subsidiary of Genmab A/S launched a tender offer for all issued and outstanding Merus N.V. common shares. As of December 12, 2025, the buyer accepted all shares that were validly tendered and not properly withdrawn.
What were the key terms of the cancelled Merus N.V. stock options?
The reported options were share options (rights to buy common shares). One covered 13,193 shares at an exercise price of $41.6 with an expiration date of May 22, 2035, and the other covered 17,688 shares at an exercise price of $48.73 with an expiration date of May 7, 2034.
When did the key tender offer milestone for Merus N.V. (MRUS) occur?
The key milestone referred to as the Acceptance Time occurred on December 12, 2025, when the purchaser accepted all Merus shares that were validly tendered and not properly withdrawn pursuant to the offer.